Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients-Reference-Cited by-同舟云学术

Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients

Published:2015-05-26 Issue:12 Volume:112 Page:1904-1910
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Ferrucci P F,Gandini S,Battaglia A,Alfieri S,Di Giacomo A M,Giannarelli D,Cappellini G C Antonini,De Galitiis F,Marchetti P,Amato G,Lazzeri A,Pala L,Cocorocchio E,Martinoli C

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2015180.pdf

Reference25 articles.

1. Ascierto PA, Simeone E, Sileni VC, Pigozzo J, Maio M, Altomonte M, Del Vecchio M, Di Guardo L, Marchetti P, Ridolfi R, Cognetti F, Testori A, Bernengo MG, Guida M, Marconcini R, Mandala M, Cimminiello C, Rinaldi G, Aglietta M, Queirolo P (2014) Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 12 (1): 116.

2. Berrocal A, Arance A, Lopez Martin JA, Soriano V, Munoz E, Alonso L, Espinosa E, Lopez Criado P, Valdivia J, Martin Algarra S Spanish Melanoma Group (2014) Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program. Melanoma Res 24 (6): 577–583.

3. Breunis WB, Tarazona-Santos E, Chen R, Kiley M, Rosenberg SA, Chanock SJ (2008) Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. J Immunother 31 (6): 586–590.

4. Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N, Roy S, Eggermont AM, Routier E, Robert C (2013) Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 24 (6): 1697–1703.

5. Di Giacomo AM, Ascierto PA, Queirolo P, Pilla L, Ridolfi R, Santinami M, Testori A, Simeone E, Guidoboni M, Maurichi A, Orgiano L, Spadola G, Del Vecchio M, Danielli R, Calabro L, Annesi D, Giannarelli D, Maccalli C, Fonsatti E, Parmiani G, Maio M (2014) Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Ann Oncol 26 (4): 798–803.

Cited by 200 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Complete Response in a Metastatic Melanoma Patient After a Single Dose of Dual Checkpoint Inhibitors Blockade Could Be Predictable: A Case Report;Cureus;2024-09-12

2. Ratio of immune indices in women of the semi-arid region;Russian Journal of Immunology;2024-08-12

3. Prognostic role of circulating cytokines and inflammation indexes for avelumab maintenance in metastatic urothelial carcinoma;Frontiers in Immunology;2024-05-10

4. Susceptibility of Melanoma Cells to Targeted Therapy Correlates with Protection by Blood Neutrophils;Cancers;2024-05-02

5. Prognostic Value of the Neutrophil-to-lymphocyte Ratio, Platelet-to- lymphocyte Ratio and Monocyte-to-lymphocyte Ratio in Melanoma Patients: A Cohort Study;Acta Dermato-Venereologica;2024-04-24